This review explores the relationship between uric acid or urate and the pathogenesis of renal impairment. The following points and conclusions are emphasized: (1) uric acid is an end product of purine degradation in humans and normally depends upon renal excretion for the majority of its elimination from the body; (2) massive urate overproduction – usually occurring acutely because of tumor lysis, rhabdomyolysis, or some other cause of rapid nucleic acid turnover or tissue destruction – tends to cause acute renal failure because of an increase of intratubular uric acid precipitation and obstruction; (3) chronic urate overproduction (with increased urate excretion) is more likely to be associated with stones or gout than with acute renal failure; (4) chronic asymptomatic hyperuricemia is unlikely to cause renal disease, gout, or stones, but is associated with cardiovascular impairment over the long term, and (5) asymptomatic hyperuricemia may serve as an indicator of renal vascular disease, or, to the extent that it may reflect insulin-induced acceleration of renal tubule urate reabsorption, hyperuricemia may serve as an indicator of insulin resistance. Therefore chronic asymptomatic hyperuricemia may predict the adverse cardiovascular consequences of insulin resistance.

1.
Sorensen LB: Degradation of uric acid in man. Metabolism 1959;8:687–703.
2.
Sorensen LB: The elimination of uric acid in man studied by means of 14C-labeled uric acid. Scand J Clin Lab Invest 1960;12(Suppl 54):1–214.
3.
Steele TH, Rieselbach RE: The renal mechanisms for urate homeostasis in normal man. Am J Med 1967;43:868–875.
4.
Rieselbach RE, Sorensen LB, Shelp WD, Steele TH: Diminished renal urate secretion per nephron as a basis for primary gout. Ann Intern Med 1970;73:359–366.
5.
Jenkins P, Rieselbach RE: Unique characteristics of the mechanism for reabsorption of filtered versus secreted urate (abstract). Proc Am Soc Clin Invest 1974;36.
6.
Steele TH, Boner G: Origins of the uricosuric response. J Clin Invest 1973;52:1368–1375.
7.
Manuel MA, Steele TH: Pyrazinamide suppression of uricosuric response to sodium chloride infusion. J Lab Clin Med 1974;83:417–427.
8.
Roch-Ramel F, Werner D, Guisan B: Urate transport in brush-border membrane of human kidney. Am J Physiol 1994;266:F797–F805.
9.
Roch-Ramel F, Guisan B, Schild L: Indirect coupling of urate and p-aminohippurate transport to sodium in human brush-border membrane vesicles. Am J Physiol 1996;270:F61–F68.
10.
Burnier M, Roch-Ramel F, Brunner HR: Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int 1996;49:1787–1790.
11.
Roch-Ramel F, Guisan B, Diezi J: Effects of uricosuric and antiuricosuric agents on urate transport in human brush-border membrane vesicles. J Pharmacol Exp Ther 1997;280:839–845.
12.
Fanelli GM Jr, Weiner IM: Pyrazinoate excretion in the chimpanzee. J Clin Invest 1973;52:1946–1957.
13.
Diamond HS: Interpretation of pharmacologic manipulation of urate transport in man. Nephron 1989;51:1–5.
14.
Steele TH: Evidence for altered renal urate reabsorption during changes in volume of the extracellular fluid. J Lab Clin Med 196974:288–299.
15.
Steele TH, Oppenheimer S: Factors affecting urate excretion following diuretic administration in man. Am J Med 1969;47:564–574.
16.
Moufid N, Weinman EJ: Hyperuricemic nephropathy; in Suki WN, Massry SG (eds): Suki and Massry’s Therapy of Renal Diseases and Related Disorders, ed 3. Boston, Kluwer, 1998, pp 541–546.
17.
Ahrens ER, Steele TH: Hyperuricemic nephropathy; in Suki WN, Massry SG (eds): Therapy of Renal Diseases and Related Disorders, ed 2. Boston, Kluwer, 1991, pp 469–476.
18.
Gutman AB: Uricosuric drugs, with special reference to probenecid and sulfinpyrazone. Adv Pharmacol Chemother 1966;4:91–142.
19.
Bennett WM, Van Zee BE, Hutchings R, Cohen LH, Norby LH, Champion C, Spargo B, Selby T: Acute renal failure from ticrynafen. N Engl J Med 1979;301:1179–1181.
20.
Coe FL, Moran E, Kavalich AG: The contribution of dietary purine overconsumption to hyperuricosuria in calcium oxalate stone formers. J Chronic Dis 1976;29:793–800.
21.
Simkin PA, Hoover PL, Paxson CS, Wilson WF: Uric acid excretion: Quantitative assessment from spot, midmorning serum and urine samples. Ann Intern Med 1979;91:44–47.
22.
Wortmann RL, Fox IH: Limited value of uric acid to creatinine ratios in estimating acid excretion. Ann Intern Med 1980;93:822–825.
23.
Talbott JH, Terplan KL: The kidney in gout. Medicine (Baltimore) 1960;39:405–462.
24.
Barlow K, Beilin L: Renal disease in primary gout. Q J Med 1968;37:79–98.
25.
Verger D, Leroux-Robert C, Ganter P, Richet G: Les tophus goutteux de la médullaire rénale urémique chronique. Nephron 1967;4:356–370.
26.
Östberg Y: Renal urate deposits in chronic renal insufficiency. Acta Med Scand 1968;183:197–201.
27.
Cannon PJ, Symchych PS, DeMartini FE: The distribution of urate in human and primate kidney. Proc Soc Exp Biol Med 1968;129:278–285.
28.
Simmonds HA, Warren DJ, Cameron JS, Potter CF, Farebrother DA: Familial gout and renal failure in young women. Clin Nephrol 1980;14:176–182.
29.
Emmerson BT, Row PG: An evaluation of the pathogenesis of the gouty kidney. Kidney Int 1975;8:65–71.
30.
Fessel WJ, Siegelaub AB, Johnson ES: Correlates and consequences of asymptomatic hyperuricemia. Arch Intern Med 1973;132:44–54.
31.
Campion E, Glynn R, Delabry M: Asymptomatic hyperuricemia. Risks and consequences in the normative aging study. Am J Med 1987;82:421–426.
32.
Berger L, Yü T-F: Renal function in gout. IV. An analysis of 525 gouty subjects including long-term follow-up studies. Am J Med 1975;59:605–613.
33.
Yü T-F, Berger L: Renal disease in primary gout: A study of 253 gout patients with proteinuria. Semin Arthritis Rheum 1975;4:293–305.
34.
Fessel WJ: Renal outcomes of gout and hyperuricemia. Am J Med 1979;67:74–82.
35.
Steele TH: Diuretic-induced hyperuricaemia; in Kelley WN (ed): Crystal-Induced Arthropathies: Clinics in Rheumatic Diseases. London, Saunders, 1977, pp 37–50.
36.
Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuno GG: Serum uric acid in essential hypertension: An indicator of renal vascular involvement. Ann Intern Med 1980;93:817–821.
37.
Klein R, Klein BE, Coroni JC, Maready J, Cassell JC, Tyroler HA: Serum uric acid: Its relationship to coronary heart disease risk factors and cardiovascular disease in Evans County, Georgia. Arch Intern Med 1973;132:401–410.
38.
Quinones GA, Natali A, Baldi S, Frascerra S, Sanna G, Ciociaro D, Ferrannini E: Effect of insulin on uric acid excretion in humans. Am J Physiol 1995;268:E1–E5.
39.
Muscelli E, Natali A, Bianchi S, Bigazzi R, Galvan AQ, Sironi AM, Frascerra S, Ciociaro D, Ferrannini E: Effect of insulin on renal sodium and uric acid handling in essential hypertension. Am J Hypertens 1996;9:746–752.
40.
Fessel WJ: High uric acid as an indicator of cardiovascular disease. Independence from obesity. Am J Med 1980;68:401–404.
41.
Reaven GF: The kidney: An unwilling accomplice in syndrome X. Am J Kidney Dis 1997;30:928–931.
42.
Beck L: Requiem for gouty nephropathy. Kidney Int 1986;30:280–287.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.